9th Jan 2019 11:25
LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan.
"The government's recently announced ten-year plan of investing in the prevention and early diagnosis of diseases, such as certain neurological, mental and oncological diseases, is a policy we have been following and striving to address for some time," said Chief Executive Satu Vainikka.
ValiRx develops cancer treatments intended to attack cancer cells only. This has the potential to produce treatments less toxic, and more effective, than chemotherapy.
At present, ValiRx is involved in an NHS-led initiative to develop its precision treatments for hormone-induced cancers, as well as a new technology for early detection.
In the second chapter of the new NHS plan, the government has said it is intending to introduce new treatments, such as gene therapy, and expand the "frontiers of medical science and innovation".
Shares in ValiRx were up 0.5% at 0.83 pence each on Wednesday morning.
Related Shares:
ValiRx